Cardiovascular Diseases Clinical Trial
Official title:
A Meta-analysis of 46 Studies Identified by the FDA on the Effect of Soy Protein on Lipid Markers (LDL-Cholesterol [LDL-C] and Total Cholesterol [TC]) as Surrogates of Cardiovascular Disease
The FDA have revised the data on soy and concluded that a heart health claim is no longer justified based on more recent studies. They are allowing and established panel for public input. The selected studies have not been meta-analyzed, therefore we will conduct a meta-analysis of the 46 FDA selected studies to assess the effect of soy protein on surrogate markers of cardiovascular disease (LDL-C and TC).
Background: The FDA in their re-evaluation of the scientific evidence for a relationship
between soy protein and reduced risk of coronary heart disease (CHD), has revised the data
included in the 1999 soy protein and CHD health claim, as well as studies published after
this authorized health claim and concluded that a heart health claim is no longer justified
based on more recent studies. The 46 identified studies have not been meta-analyzed.
Need for proposed research: To meta-analyse the 46 identified studies to provide the highest
level of evidence to aid in the final decision of the soy protein and reduced risk of CHD
health claim.
Objective: To provide evidence-based guidance for publich health policy, health claims, and
nutrition guidelines relating to soy, we will conduct a meta-analysis of the 46 FDA
identified studies of the effect of soy protein on surrogate markers of cardiovascular
disease.
Design: The conduct of the meta-analysis will follow the Cochrane handbook for Systematic
Reviews of interventions. The reporting will follow the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) guidelines.
Data sources and study selection: We will include the 46 studies pre-selected by the FDA in
the Proposed Rule, Soy Protein and Coronary Heart Disease (Docket No. FDA-2017-N-0763).
Data extraction: Two independent investigators will extract study information (study design,
sample size, subject characteristics, soy form, dose, comparator, follow-up, background diet,
outcome data).
Outcomes: Effects of soy protein intake on LDL-C and TC.
Data synthesis: Mean differences will be pooled using the generic inverse variance method
with random-effects model even in the absence of statistically significance between-study
heterogeneity, as they yield more conservative summary effect estimates in the presence of
residual heterogeneity. Paired analysis will be applied fro crossover trials. Heterogeneity
will e assessed by the Cochran Q statistic and quantified by the I2 statistic. To explore
sources of heterogeneity, we will conduct sensitivity analysis, in which each study is
systematically removed. We will also explore sources of heterogeneity by a priori subgroup
analyses by baseline LDL-C levels (<135 mg/dl vs >=135mg/dl), soy dose (<25 g/d vs >= 25
g/d), soy protein food (Isolated soy protein, soy food, soy milk, etc), comparator (animal
protein, dairy protein, meat protein), follow-up (median), and categories given by the FDA
(baseline cholesterol level [desirable or borderline, high, or normal, borderline, and high],
how soy was provided in the studies [feeding or substitution, added to diet], by a mixture of
type of soy, how it was provided and baseline cholesterol level [1)Desirable or borderline
cholesterol level, added ISP; 2) Desirable or borderline cholesterol level, feeding or
substitution studies with ISP; 3) Desirable or borderline cholesterol level, added soy foods;
4)Desirable or borderline cholesterol level, feeding or substitution studies with soy foods;
5) Normal, borderline, and high cholesterol levels, feeding or substitution studies with ISP;
6) High cholesterol level, added ISP; 7) High cholesterol level, feeding or substitution
studies with ISP; 8) High cholesterol level, added soy foods; and 9) High cholesterol level,
feeding soy foods]), and risk of bias. Meta-regression analysis will assess the significance.
Publication bias will be assess by visual inspection of funnel plots and by the use of Egger
and Begg's tests. If publication bias is suspected, then we will attempt to adjust for funnel
plot asymmetry by imputing the missing study data using the Duval and Tweedie trim and fill
method. Dose-reponse analyses will be conducted using the metareg and mkspline commands.
Knowledge translation plan: The results will be disseminated in two stages, first, by the Soy
Nutrition Institute in a response to the Proposed Rule, Soy Protein and Coronary Heart
Disease, and by a publication in a high impact factor journal.
Significance: The meta-analysis will aid in knowledge translation related to the role of soy
protein intake and surrogate markers of cardiovascular disease (LDL-C and TC), strengthening
the evidence-based for guidelines and health claims, and improving health outcomes by
educating healthcare providers and patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04098172 -
Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR
|
N/A |